Tratamiento farmacológico y seguimiento del síndrome de Cushing

Dang, 2007, Pharmacological management of Cushing's syndrome: an update, Arq Bras Endocrinol Metabol, 51, 1339, 10.1590/S0004-27302007000800020 Trainer, 1994, Cushing's syndrome: Therapy directed at the adrenal glands, Endocrinol Metab Clin North Am, 23, 571, 10.1016/S0889-8529(18)30085-9 Sonino, 2005, Pharmacologic management of Cushing's syndrome; new target for therapy, Treat Endocrinol, 4, 87, 10.2165/00024677-200504020-00003 T'Sjoen, 2002, Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline, J Endocrinol Invest, 25, 172, 10.1007/BF03343983 Pivonello, 1999, Complete remission of Nelson's syndrome after 1-year treatment with cabergoline, J Endocrinol Invest, 22, 860, 10.1007/BF03343660 Pivonello, 2009, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery, J Clin Endocrinol Metab, 94, 223, 10.1210/jc.2008-1533 Pivonello, 2008, Cushing's syndrome, Endocrinol Metab Clin North Am, 37, 135, 10.1016/j.ecl.2007.10.010 Lamberts, 1994, A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome, J Clin Endocrinol Metab, 78, 17 Pivonello, 2005, Cabergoline plus lanreotide for ectopic Cushing's syndrome, N Engl J Med, 352, 2457, 10.1056/NEJM200506093522322 Engelhardt, 1994, Steroid biosyntesis inhibitors in Cushing's syndrome, Clin Invest, 72, 481, 10.1007/BF00207474 Biller, 2008, Treatment of adrenocorticotropin-dependent Cushing's syndrome: a Consensus Statement, J Clin Endocrinol Metab, 93, 2454, 10.1210/jc.2007-2734 Verhelst, 1991, Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome, Clin Endocrinol (Oxf), 35, 169, 10.1111/j.1365-2265.1991.tb03517.x Oelkers, 1986, Primary adrenocortical micronodular adenomatosis causing Cushing's syndrome. Effects of ketoconazole on steroid production and in vitro performance of adrenal cells, Acta Endocrinol (Copehn), 113, 370, 10.1530/acta.0.1130370 Leal-Cerro, 1990, Estudio y valoración de las aplicaciones del antimicótico ketoconazol en distintas patologías endocrinológicas. Perspectivas actuales y futuras. Stalla, 1988, Ketoconazole inhibits corticotrophin cell function in vitro, Endocrinology, 122, 618, 10.1210/endo-122-2-618 Relimpio Astolfi, 1992, Hipertransaminasemia inducida por ketoconazol, Endocrinología, 39, 42 Amado, 1990, Successful treatment with ketoconazole of Cushing's syndrome in pregnancy, Postgrad Med J, 66, 221, 10.1136/pgmj.66.773.221 Krakoff, 2001, Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome, J Clin Endocrinol Metab, 86, 4104 Drake, 1998, Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis, J Clin Endocrinol Metab, 83, 3542 Touitou, 1985, o,p’-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis, Eur J Clin Pharmacol, 29, 483, 10.1007/BF00613466 Chu, 2001, Successful long-term treatment of refractory Cushing's disease with high-dose mifrepristone (RU 486), J Clin Endocrinol Metab, 86, 3568 Páez Pereda, 2001, Retinoic acid prevents experimental Cushing's syndrome, J Clin Invest, 108, 1123, 10.1172/JCI11098 Riedl, 2006, Long term control of hypercortisolism with fluconazole: case repot and in vitro studies, Eur J Endocrinol, 154, 519, 10.1530/eje.1.02120 Heaney, 2002, Functional PPAR-gamma receptor is a novel therapeutic target for ACTHsecreting pituitary adenomas, Nat Med, 8, 1281, 10.1038/nm784 Heaney, 2003, PPAR-ganma receptor ligands: Novel therapy for pituitary adenomas, J Clin Invest, 111, 1381, 10.1172/JCI200316575 Cannavo, 2005, Effectiveness of long term rosiglitazone administration in patients with Cushing's disease, Clin Endocrinol (Oxf), 63, 118, 10.1111/j.1365-2265.2005.02285.x Suri, 2005, Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease, J Clin Endocrinol Metab, 90, 1340, 10.1210/jc.2004-1746 Lesche, 2009, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro, J Clin Endocrinol Metab, 94, 654, 10.1210/jc.2008-1919 Hofland, 2005, The multi-ligand somatostain analogue SOM 230 inhibit ACTH secretion by cultured human corticotroph adenomas via somatostin receptor type 5, Eur J Endocrinol, 152, 645, 10.1530/eje.1.01876 Batista, 2006, The effects of som230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas, J Clin Endocrinol Metab, 91, 4482, 10.1210/jc.2006-1245 Boscaro, 2006, Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease Boscaro, 2009, Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial, J Clin Endocrinol Metab, 94, 115, 10.1210/jc.2008-1008 Moyes, 2009, Treatment of Nelson's syndrome with temozolomide, Eur J Endocrinol, 160, 115, 10.1530/EJE-08-0557 Nethaji, 2008 Findling, 2006, Cushing's syndrome: Important issues in diagnosis and management, J Clin Endocrinol Metab, 91, 3746, 10.1210/jc.2006-0997 Barker, 2003, Transsphenoidal surgery for pituitary tumors in the united states, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume, J Clin Endocrinol Metab, 88, 4709, 10.1210/jc.2003-030461 Atkinson, 2005, Long term remission rates after pituitary surgery for Cushing's disease: the need for a long term surveillance, Clin Endocrinol (Oxf), 63, 549, 10.1111/j.1365-2265.2005.02380.x Trainer, 1993, Transphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment, Clin Endocrinol (Oxf), 3, 73, 10.1111/j.1365-2265.1993.tb00975.x Pereira, 2003, Long term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease, J Clin Endocrinol Metab, 88, 5858, 10.1210/jc.2003-030751 Bochicchio, 1995, Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group, J Clin Endocrinol Metab, 80, 3114 Newell-Price, 2002, Transsphenoidal surgery for Cushing's disease: defining cure and following outcome, Clin Endocrinol (Oxf), 56, 19, 10.1046/j.1365-2265.2002.01369.x Woo, 2005, Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas, J Clin Endocrinol Metab, 90, 4963, 10.1210/jc.2005-0070 Lamberts, 1995, Transphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and long term follow up, J Clin Endocrinol Metab, 80, 3111 Locatelli, 2005, The strategy of immediate reoperation for transphenoidal surgery for Cushing's disease, J Clin Endocrinol Metab, 90, 5478, 10.1210/jc.2004-2436 Esposito, 2006, Early morning cortisol level as a predictor of remission after transphenoidal surgery of Cushing disease, J Clin Endocrinol Metab, 91, 7, 10.1210/jc.2005-1204 Vázquez, 2006 Salenave, 2004, Pituitary magnetic resonance imaging findings do not influence surgical outcome in adrenocorticotropin-secreting microadenomas, J Clin Endocrinol Metab, 89, 3371, 10.1210/jc.2003-031908 Arnaldi, 2003, Diagnosis and complications of Cushing's syndrome: A consensus statement, J Clin Endocrinol Metab, 88, 5593, 10.1210/jc.2003-030871 Guilhaume, 1988, Transphenoidal pituitary surgery for the treatment of Cushing's disease: results in 64 patients and long term follow up studies, J Clin Endocrinol Metab, 66, 1056, 10.1210/jcem-66-5-1056